Cargando…
Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis
IMPORTANCE: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. OBJEC...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568447/ https://www.ncbi.nlm.nih.gov/pubmed/37819650 http://dx.doi.org/10.1001/jamapsychiatry.2023.3850 |
_version_ | 1785119362268528640 |
---|---|
author | Haas, Shalaila S. Ge, Ruiyang Agartz, Ingrid Amminger, G. Paul Andreassen, Ole A. Bachman, Peter Baeza, Inmaculada Choi, Sunah Colibazzi, Tiziano Cropley, Vanessa L. de la Fuente-Sandoval, Camilo Ebdrup, Bjørn H. Fortea, Adriana Fusar-Poli, Paolo Glenthøj, Birte Yding Glenthøj, Louise Birkedal Haut, Kristen M. Hayes, Rebecca A. Heekeren, Karsten Hooker, Christine I. Hwang, Wu Jeong Jahanshad, Neda Kaess, Michael Kasai, Kiyoto Katagiri, Naoyuki Kim, Minah Kindler, Jochen Koike, Shinsuke Kristensen, Tina D. Kwon, Jun Soo Lawrie, Stephen M. Lebedeva, Irina Lee, Jimmy Lemmers-Jansen, Imke L. J. Lin, Ashleigh Ma, Xiaoqian Mathalon, Daniel H. McGuire, Philip Michel, Chantal Mizrahi, Romina Mizuno, Masafumi Møller, Paul Mora-Durán, Ricardo Nelson, Barnaby Nemoto, Takahiro Nordentoft, Merete Nordholm, Dorte Omelchenko, Maria A. Pantelis, Christos Pariente, Jose C. Raghava, Jayachandra M. Reyes-Madrigal, Francisco Røssberg, Jan I. Rössler, Wulf Salisbury, Dean F. Sasabayashi, Daiki Schall, Ulrich Smigielski, Lukasz Sugranyes, Gisela Suzuki, Michio Takahashi, Tsutomu Tamnes, Christian K. Theodoridou, Anastasia Thomopoulos, Sophia I. Thompson, Paul M. Tomyshev, Alexander S. Uhlhaas, Peter J. Værnes, Tor G. van Amelsvoort, Therese A. M. J. van Erp, Theo G. M. Waltz, James A. Wenneberg, Christina Westlye, Lars T. Wood, Stephen J. Zhou, Juan H. Hernaus, Dennis Jalbrzikowski, Maria Kahn, René S. Corcoran, Cheryl M. Frangou, Sophia |
author_facet | Haas, Shalaila S. Ge, Ruiyang Agartz, Ingrid Amminger, G. Paul Andreassen, Ole A. Bachman, Peter Baeza, Inmaculada Choi, Sunah Colibazzi, Tiziano Cropley, Vanessa L. de la Fuente-Sandoval, Camilo Ebdrup, Bjørn H. Fortea, Adriana Fusar-Poli, Paolo Glenthøj, Birte Yding Glenthøj, Louise Birkedal Haut, Kristen M. Hayes, Rebecca A. Heekeren, Karsten Hooker, Christine I. Hwang, Wu Jeong Jahanshad, Neda Kaess, Michael Kasai, Kiyoto Katagiri, Naoyuki Kim, Minah Kindler, Jochen Koike, Shinsuke Kristensen, Tina D. Kwon, Jun Soo Lawrie, Stephen M. Lebedeva, Irina Lee, Jimmy Lemmers-Jansen, Imke L. J. Lin, Ashleigh Ma, Xiaoqian Mathalon, Daniel H. McGuire, Philip Michel, Chantal Mizrahi, Romina Mizuno, Masafumi Møller, Paul Mora-Durán, Ricardo Nelson, Barnaby Nemoto, Takahiro Nordentoft, Merete Nordholm, Dorte Omelchenko, Maria A. Pantelis, Christos Pariente, Jose C. Raghava, Jayachandra M. Reyes-Madrigal, Francisco Røssberg, Jan I. Rössler, Wulf Salisbury, Dean F. Sasabayashi, Daiki Schall, Ulrich Smigielski, Lukasz Sugranyes, Gisela Suzuki, Michio Takahashi, Tsutomu Tamnes, Christian K. Theodoridou, Anastasia Thomopoulos, Sophia I. Thompson, Paul M. Tomyshev, Alexander S. Uhlhaas, Peter J. Værnes, Tor G. van Amelsvoort, Therese A. M. J. van Erp, Theo G. M. Waltz, James A. Wenneberg, Christina Westlye, Lars T. Wood, Stephen J. Zhou, Juan H. Hernaus, Dennis Jalbrzikowski, Maria Kahn, René S. Corcoran, Cheryl M. Frangou, Sophia |
collection | PubMed |
description | IMPORTANCE: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. OBJECTIVE: To quantify deviations from the normative range of neuroanatomical variation in individuals at clinical high risk for psychosis (CHR-P) and evaluate their overlap with healthy variation and their association with positive symptoms, cognition, and conversion to a psychotic disorder. DESIGN, SETTING, AND PARTICIPANTS: This case-control study used clinical-, IQ-, and neuroimaging software (FreeSurfer)–derived regional measures of cortical thickness (CT), cortical surface area (SA), and subcortical volume (SV) from 1340 individuals with CHR-P and 1237 healthy individuals pooled from 29 international sites participating in the Enhancing Neuroimaging Genetics Through Meta-analysis (ENIGMA) Clinical High Risk for Psychosis Working Group. Healthy individuals and individuals with CHR-P were matched on age and sex within each recruitment site. Data were analyzed between September 1, 2021, and November 30, 2022. MAIN OUTCOMES AND MEASURES: For each regional morphometric measure, deviation scores were computed as z scores indexing the degree of deviation from their normative means from a healthy reference population. Average deviation scores (ADS) were also calculated for regional CT, SA, and SV measures and globally across all measures. Regression analyses quantified the association of deviation scores with clinical severity and cognition, and 2-proportion z tests identified case-control differences in the proportion of individuals with infranormal (z < −1.96) or supranormal (z > 1.96) scores. RESULTS: Among 1340 individuals with CHR-P, 709 (52.91%) were male, and the mean (SD) age was 20.75 (4.74) years. Among 1237 healthy individuals, 684 (55.30%) were male, and the mean (SD) age was 22.32 (4.95) years. Individuals with CHR-P and healthy individuals overlapped in the distributions of the observed values, regional z scores, and all ADS values. For any given region, the proportion of individuals with CHR-P who had infranormal or supranormal values was low (up to 153 individuals [<11.42%]) and similar to that of healthy individuals (<115 individuals [<9.30%]). Individuals with CHR-P who converted to a psychotic disorder had a higher percentage of infranormal values in temporal regions compared with those who did not convert (7.01% vs 1.38%) and healthy individuals (5.10% vs 0.89%). In the CHR-P group, only the ADS SA was associated with positive symptoms (β = −0.08; 95% CI, −0.13 to −0.02; P = .02 for false discovery rate) and IQ (β = 0.09; 95% CI, 0.02-0.15; P = .02 for false discovery rate). CONCLUSIONS AND RELEVANCE: In this case-control study, findings suggest that macroscale neuromorphometric measures may not provide an adequate explanation of psychosis risk. |
format | Online Article Text |
id | pubmed-10568447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-105684472023-10-13 Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis Haas, Shalaila S. Ge, Ruiyang Agartz, Ingrid Amminger, G. Paul Andreassen, Ole A. Bachman, Peter Baeza, Inmaculada Choi, Sunah Colibazzi, Tiziano Cropley, Vanessa L. de la Fuente-Sandoval, Camilo Ebdrup, Bjørn H. Fortea, Adriana Fusar-Poli, Paolo Glenthøj, Birte Yding Glenthøj, Louise Birkedal Haut, Kristen M. Hayes, Rebecca A. Heekeren, Karsten Hooker, Christine I. Hwang, Wu Jeong Jahanshad, Neda Kaess, Michael Kasai, Kiyoto Katagiri, Naoyuki Kim, Minah Kindler, Jochen Koike, Shinsuke Kristensen, Tina D. Kwon, Jun Soo Lawrie, Stephen M. Lebedeva, Irina Lee, Jimmy Lemmers-Jansen, Imke L. J. Lin, Ashleigh Ma, Xiaoqian Mathalon, Daniel H. McGuire, Philip Michel, Chantal Mizrahi, Romina Mizuno, Masafumi Møller, Paul Mora-Durán, Ricardo Nelson, Barnaby Nemoto, Takahiro Nordentoft, Merete Nordholm, Dorte Omelchenko, Maria A. Pantelis, Christos Pariente, Jose C. Raghava, Jayachandra M. Reyes-Madrigal, Francisco Røssberg, Jan I. Rössler, Wulf Salisbury, Dean F. Sasabayashi, Daiki Schall, Ulrich Smigielski, Lukasz Sugranyes, Gisela Suzuki, Michio Takahashi, Tsutomu Tamnes, Christian K. Theodoridou, Anastasia Thomopoulos, Sophia I. Thompson, Paul M. Tomyshev, Alexander S. Uhlhaas, Peter J. Værnes, Tor G. van Amelsvoort, Therese A. M. J. van Erp, Theo G. M. Waltz, James A. Wenneberg, Christina Westlye, Lars T. Wood, Stephen J. Zhou, Juan H. Hernaus, Dennis Jalbrzikowski, Maria Kahn, René S. Corcoran, Cheryl M. Frangou, Sophia JAMA Psychiatry Original Investigation IMPORTANCE: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. OBJECTIVE: To quantify deviations from the normative range of neuroanatomical variation in individuals at clinical high risk for psychosis (CHR-P) and evaluate their overlap with healthy variation and their association with positive symptoms, cognition, and conversion to a psychotic disorder. DESIGN, SETTING, AND PARTICIPANTS: This case-control study used clinical-, IQ-, and neuroimaging software (FreeSurfer)–derived regional measures of cortical thickness (CT), cortical surface area (SA), and subcortical volume (SV) from 1340 individuals with CHR-P and 1237 healthy individuals pooled from 29 international sites participating in the Enhancing Neuroimaging Genetics Through Meta-analysis (ENIGMA) Clinical High Risk for Psychosis Working Group. Healthy individuals and individuals with CHR-P were matched on age and sex within each recruitment site. Data were analyzed between September 1, 2021, and November 30, 2022. MAIN OUTCOMES AND MEASURES: For each regional morphometric measure, deviation scores were computed as z scores indexing the degree of deviation from their normative means from a healthy reference population. Average deviation scores (ADS) were also calculated for regional CT, SA, and SV measures and globally across all measures. Regression analyses quantified the association of deviation scores with clinical severity and cognition, and 2-proportion z tests identified case-control differences in the proportion of individuals with infranormal (z < −1.96) or supranormal (z > 1.96) scores. RESULTS: Among 1340 individuals with CHR-P, 709 (52.91%) were male, and the mean (SD) age was 20.75 (4.74) years. Among 1237 healthy individuals, 684 (55.30%) were male, and the mean (SD) age was 22.32 (4.95) years. Individuals with CHR-P and healthy individuals overlapped in the distributions of the observed values, regional z scores, and all ADS values. For any given region, the proportion of individuals with CHR-P who had infranormal or supranormal values was low (up to 153 individuals [<11.42%]) and similar to that of healthy individuals (<115 individuals [<9.30%]). Individuals with CHR-P who converted to a psychotic disorder had a higher percentage of infranormal values in temporal regions compared with those who did not convert (7.01% vs 1.38%) and healthy individuals (5.10% vs 0.89%). In the CHR-P group, only the ADS SA was associated with positive symptoms (β = −0.08; 95% CI, −0.13 to −0.02; P = .02 for false discovery rate) and IQ (β = 0.09; 95% CI, 0.02-0.15; P = .02 for false discovery rate). CONCLUSIONS AND RELEVANCE: In this case-control study, findings suggest that macroscale neuromorphometric measures may not provide an adequate explanation of psychosis risk. American Medical Association 2023-10-11 /pmc/articles/PMC10568447/ /pubmed/37819650 http://dx.doi.org/10.1001/jamapsychiatry.2023.3850 Text en Copyright 2023 ENIGMA Clinical High Risk for Psychosis Working Group. JAMA Psychiatry. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Haas, Shalaila S. Ge, Ruiyang Agartz, Ingrid Amminger, G. Paul Andreassen, Ole A. Bachman, Peter Baeza, Inmaculada Choi, Sunah Colibazzi, Tiziano Cropley, Vanessa L. de la Fuente-Sandoval, Camilo Ebdrup, Bjørn H. Fortea, Adriana Fusar-Poli, Paolo Glenthøj, Birte Yding Glenthøj, Louise Birkedal Haut, Kristen M. Hayes, Rebecca A. Heekeren, Karsten Hooker, Christine I. Hwang, Wu Jeong Jahanshad, Neda Kaess, Michael Kasai, Kiyoto Katagiri, Naoyuki Kim, Minah Kindler, Jochen Koike, Shinsuke Kristensen, Tina D. Kwon, Jun Soo Lawrie, Stephen M. Lebedeva, Irina Lee, Jimmy Lemmers-Jansen, Imke L. J. Lin, Ashleigh Ma, Xiaoqian Mathalon, Daniel H. McGuire, Philip Michel, Chantal Mizrahi, Romina Mizuno, Masafumi Møller, Paul Mora-Durán, Ricardo Nelson, Barnaby Nemoto, Takahiro Nordentoft, Merete Nordholm, Dorte Omelchenko, Maria A. Pantelis, Christos Pariente, Jose C. Raghava, Jayachandra M. Reyes-Madrigal, Francisco Røssberg, Jan I. Rössler, Wulf Salisbury, Dean F. Sasabayashi, Daiki Schall, Ulrich Smigielski, Lukasz Sugranyes, Gisela Suzuki, Michio Takahashi, Tsutomu Tamnes, Christian K. Theodoridou, Anastasia Thomopoulos, Sophia I. Thompson, Paul M. Tomyshev, Alexander S. Uhlhaas, Peter J. Værnes, Tor G. van Amelsvoort, Therese A. M. J. van Erp, Theo G. M. Waltz, James A. Wenneberg, Christina Westlye, Lars T. Wood, Stephen J. Zhou, Juan H. Hernaus, Dennis Jalbrzikowski, Maria Kahn, René S. Corcoran, Cheryl M. Frangou, Sophia Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis |
title | Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis |
title_full | Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis |
title_fullStr | Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis |
title_full_unstemmed | Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis |
title_short | Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis |
title_sort | normative modeling of brain morphometry in clinical high risk for psychosis |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568447/ https://www.ncbi.nlm.nih.gov/pubmed/37819650 http://dx.doi.org/10.1001/jamapsychiatry.2023.3850 |
work_keys_str_mv | AT normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT haasshalailas normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT geruiyang normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT agartzingrid normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT ammingergpaul normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT andreassenolea normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT bachmanpeter normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT baezainmaculada normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT choisunah normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT colibazzitiziano normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT cropleyvanessal normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT delafuentesandovalcamilo normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT ebdrupbjørnh normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT forteaadriana normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT fusarpolipaolo normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT glenthøjbirteyding normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT glenthøjlouisebirkedal normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT hautkristenm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT hayesrebeccaa normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT heekerenkarsten normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT hookerchristinei normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT hwangwujeong normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT jahanshadneda normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT kaessmichael normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT kasaikiyoto normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT katagirinaoyuki normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT kimminah normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT kindlerjochen normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT koikeshinsuke normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT kristensentinad normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT kwonjunsoo normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT lawriestephenm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT lebedevairina normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT leejimmy normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT lemmersjansenimkelj normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT linashleigh normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT maxiaoqian normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT mathalondanielh normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT mcguirephilip normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT michelchantal normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT mizrahiromina normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT mizunomasafumi normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT møllerpaul normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT moraduranricardo normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT nelsonbarnaby normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT nemototakahiro normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT nordentoftmerete normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT nordholmdorte normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT omelchenkomariaa normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT pantelischristos normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT parientejosec normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT raghavajayachandram normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT reyesmadrigalfrancisco normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT røssbergjani normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT rosslerwulf normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT salisburydeanf normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT sasabayashidaiki normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT schallulrich normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT smigielskilukasz normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT sugranyesgisela normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT suzukimichio normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT takahashitsutomu normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT tamneschristiank normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT theodoridouanastasia normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT thomopoulossophiai normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT thompsonpaulm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT tomyshevalexanders normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT uhlhaaspeterj normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT værnestorg normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT vanamelsvoortthereseamj normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT vanerptheogm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT waltzjamesa normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT wennebergchristina normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT westlyelarst normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT woodstephenj normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT zhoujuanh normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT hernausdennis normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT jalbrzikowskimaria normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT kahnrenes normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT corcorancherylm normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis AT frangousophia normativemodelingofbrainmorphometryinclinicalhighriskforpsychosis |